A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma

We compared the safety and efficacy of siltuximab (S), an anti-interleukin-6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc)+B in patients with relapsed/refractory multiple myeloma in a randomized phase II study. Siltuximab was given by 6 mg/kg IV every 2 weeks. On progression,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Orlowski, Robert Z., Gercheva, Liana, Williams, Cathy, Sutherland, Heather, Robak, Tadeusz, Masszi, Tamás, Goranova-Marinova, Vesselina, Dimopoulos, Meletios A., Cavenagh, James D., Špička, Ivan, Maiolino, Angelo, Suvorov, Alexander, Bladé, Joan, Samoylova, Olga, Puchalski, Thomas A., Reddy, Manjula, Bandekar, Rajesh, van de Velde, Helgi, Xie, Hong, Rossi, Jean-François
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737504/
https://ncbi.nlm.nih.gov/pubmed/25294016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados